Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer

By McKay Rana R.   Gray Kathryn P.   Hayes Julia H.   Bubley Glenn J.   Rosenberg Jonathan E.   Hussain Arif   Kantoff Philip W.   Taplin Mary-Ellen  

Cancer, Vol. 121, Iss. 15, 2015-08 ,pp. : 2603-2611

Blackwell Publishing

Access to resources Recommend Favorite

Aggressive therapy not necessary for low-grade, localised prostate cancer

By  

Inpharma, Vol. 1, Iss. 1487, 2005-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

High-risk localised prostate cancer: multimodal treatment strategies combining neoadjuvant hormonal therapy and/or chemotherapy with radical prostatectomy

By Eastham James A  

Expert Opinion on Emerging Drugs, Vol. 8, Iss. 2, 2003-11 ,pp. : 291-295

Informa Healthcare

Access to resources Recommend Favorite

Multimodal treatment strategies combining neoadjuvant hormonal therapy and/or chemotherapy with radical prostatectomy in high-risk localised prostate cancer

By Eastham James A  

Expert Opinion on Investigational Drugs, Vol. 13, Iss. 1, 2004-01 ,pp. : 39-46

Informa Healthcare

Access to resources Recommend Favorite

MRC PR07: A Randomised Trial of Hormone Therapy ± Radiotherapy in Advanced Localised Prostate Cancer (ISRCTN 24991896)*

By  

UroOncology, Vol. 2, Iss. 2, 2002-01 ,pp. : 59-61

Ashgate Publishing Ltd

Access to resources Recommend Favorite